https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 How well have projected lung cancer rates predicted the actual observed rates? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45200 Wed 26 Oct 2022 14:32:12 AEDT ]]> Trends and projections of cause-specific premature mortality in Australia to 2044: a statistical modelling study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54893 Wed 20 Mar 2024 13:33:42 AEDT ]]> Pathways to diagnosis of endometrial and ovarian cancer in the 45 and Up Study cohort https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51044 Wed 16 Aug 2023 11:19:37 AEST ]]> Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51025 Wed 16 Aug 2023 10:02:34 AEST ]]> Lynch syndrome testing of colorectal cancer patients in a high-income country with universal healthcare: a retrospective study of current practice and gaps in seven australian hospitals https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51759 70 years). Of 38 patients with high-risk tumour test results and genetics services referral, diagnostic testing was carried out for 25 (89%) and identified a LS pathogenic/likely pathogenic variant for 11 patients (44% of 25; 0.7% of 1,624 patients). Conclusions: Given the LS testing and referral gaps, further work is needed to identify strategies for successful integration of LS testing into clinical care, and provide a model for hereditary cancers and broader genomic medicine. Standardised reporting may help clinicians interpret tumour test results and initiate further actions.]]> Wed 13 Mar 2024 08:10:01 AEDT ]]> Accurate categorisation of menopausal status for research studies: a step-by-step guide and detailed algorithm considering age, self-reported menopause and factors potentially masking the occurrence of menopause. https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50708 Wed 02 Aug 2023 15:00:51 AEST ]]> Large-scale systematic analysis of exposure to multiple cancer risk factors and the associations between exposure patterns and cancer incidence. https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49325 Tue 14 Nov 2023 14:39:43 AEDT ]]> Lung cancer mortality in Australia in the twenty-first century: how many lives can be saved with effective tobacco control? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37419 Thu 27 Jan 2022 15:57:36 AEDT ]]> Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51477 Thu 07 Sep 2023 10:46:14 AEST ]]> Trends in colon and rectal cancer mortality in Australia from 1972 to 2015 and associated projections to 2040 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52259 Thu 05 Oct 2023 18:33:05 AEDT ]]> Projections of smoking-related cancer mortality in Australia to 2044 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52851 30%. For each group, an age–period– cohort model or generalised linear model with cigarette smoking exposure as a covariate was selected based on the model fit statistics and validation using observed data. The smoking-attributable fraction (SAF) was calculated for each smoking-related cancer using Australian smoking prevalence data and published relative risks. Results: Despite the decreasing mortality rates projected for the period 2015–2019 to 2040–2044 for both men and women, the overall number of smoking-related cancer deaths is estimated to increase by 28.7% for men and 35.8% for women: from 138 707 (77 839 men and 60 868 women) in 2015–2019 to 182 819 (100 153 men and 82 666 women) in 2040–2044. Over the period 2020–2044, there will be 254 583 cancer deaths (173 943 men and 80 640 women) directly attributable to smoking, with lung, larynx, oesophagus and oral (comprising lip, oral cavity and pharynx) cancers having the largest SAFs. Interpretation: Cigarette smoking will cause over 250 000 cancer deaths in Australia from 2020 to 2044. Continued efforts in tobacco control remain a public health priority, even in countries where smoking prevalence has substantially declined.]]> Mon 30 Oct 2023 09:54:19 AEDT ]]> Building capacity from within: Qualitative evaluation of a training program aimed at upskilling healthcare workers in delivering an evidence-based implementation approach https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44769 Mon 24 Oct 2022 09:03:39 AEDT ]]> Changes in cancer incidence and mortality in Australia over the period 1996-2015 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38225 Mon 16 Aug 2021 15:40:53 AEST ]]> Raking of data from a large Australian cohort study improves generalisability of estimates of prevalence of health and behaviour characteristics and cancer incidence https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51422 Mon 04 Sep 2023 14:57:22 AEST ]]> Health system costs and days in hospital for colorectal cancer patients in New South Wales, Australia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51405 Mon 04 Sep 2023 14:53:07 AEST ]]> Human Genetics Society of Australasia Position Statement: Use of Polygenic Scores in Clinical Practice and Population Health https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51355 Fri 01 Sep 2023 13:43:26 AEST ]]>